NR1D1 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
When Eng arrived at Amylin's San Diego headquarters, he was astonished to discover how much information Amylin's scientists had already figured out about exendin-4 in the brief period of time after Young saw his poster, which convinced him that Amylin was the right company to partner with. Amylin went on to create exenatide, a synthetic version of exendin-4, and later formed an alliance with Lilly in 2002 to bring the drug to market. Exenatide was predicted by Amylin scientist Alain Baron to begin undergoing the Food and Drug Administration's approval process in 2004. Exenatide was approved by the FDA in April 2005, for people whose diabetes is not well controlled on other oral medications. This was a landmark event which proved that targeting the GLP-1 receptor was a viable strategy and inspired other pharmaceutical companies to focus their research and development on that receptor. In 2011, Lilly and Amylin dissolved their partnership, with Amylin keeping the rights to exenatide. Meanwhile, Lilly had been awakened to the possibilities of this class of drugs and continued to develop newer drugs of the same class. By October 2024, the blockbuster drug tirzepatide had transformed Lilly into the most valuable drug company in the world.
"Adequate calcium throughout life, as part of a well-balanced diet, may reduce the risk of osteoporosis." "Adequate calcium as part of a healthful diet, along with physical activity, may reduce the risk of osteoporosis in later life." "Adequate calcium and vitamin D throughout life, as part of a well-balanced diet, may reduce the risk of osteoporosis." "Adequate calcium and vitamin D as part of a healthful diet, along with physical activity, may reduce the risk of osteoporosis in later life." In the same year, the European Food Safety Authority also approved a dietary supplement health claim for calcium and vitamin D and the reduction of the risk of osteoporotic fractures by reducing bone loss. The U.S. FDA also approved Qualified Health Claims (QHCs) for various health conditions for calcium, selenium and chromium picolinate. QHCs are supported by scientific evidence, but do not meet the more rigorous "significant scientific agreement" standard required for an authorized health claim. If dietary supplement companies choose to make such a claim then the FDA stipulates the exact wording of the QHC to be used on labels and in marketing materials. The wording can be onerous: "One study suggests that selenium intake may reduce the risk of bladder cancer in women. However, one smaller study showed no reduction in risk.
There are 25 known isotopes of potassium, three of which occur naturally: 39K (93.3%), 40K (0.0117%), and 41K (6.7%) (by mole fraction). Naturally occurring 40K has a half-life of 1.250×109 years. It decays to stable 40Ar by electron capture or positron emission (11.2%) or to stable 40Ca by beta decay (88.8%). This decay results in a relatively higher concentration of Argon in the atmosphere. The decay of 40K to 40Ar is the basis of a common method for dating rocks. The conventional potassium–argon dating method depends on the assumption that the rocks contained no argon at the time of formation and that all the subsequent radiogenic argon (40Ar) was quantitatively retained. Minerals are dated by measurement of the concentration of potassium and the amount of radiogenic 40Ar that has accumulated. The minerals best suited for dating include biotite, muscovite, metamorphic hornblende, and volcanic feldspar; whole rock samples from volcanic flows and shallow instrusives can also be dated if they are unaltered. Apart from dating, potassium isotopes have been used as tracers in studies of weathering and for nutrient cycling studies because potassium is a macronutrient required for life on Earth. 40K occurs in natural potassium (and thus in some commercial salt substitutes) in sufficient quantity that large bags of those substitutes can be used as a radioactive source for classroom demonstrations. 40K is the radioisotope with the largest abundance in the human body. In healthy animals and people, 40K represents the largest source of radioactivity, greater even than 14C.
Sources: en.wikipedia.org
Exchanges between OECD governments benefit from the information, analysis, and preparation of the OECD Secretariat. The secretariat collects data, monitors trends, and analyses and forecasts economic developments. Under the direction and guidance of member governments, it also researches social changes or evolving patterns in trade, environment, education, agriculture, technology, taxation and other areas. The secretariat is organised in directorates:
== Research == From the beginning of his career Bengt Mannervik studied enzymes of glutathione metabolism, including studies of levels in different tissues, structure and catalytic activity of glutathione transferase, a purification method, a detailed review on the isoenzymes of glutathione transferase, and many others. These publications have had a major influence on the field of glutathione biochemistry. Each of those mentioned above, together with three others, had been cited more than 1000 times by the end of 2024, the first more than 5000 times, leading to an h index of 89, as calculated by Google Scholar. In all he has had nearly 600 publications, with a combined total of more than 47000 citations. His interest in glutathione transferases has continued after his retirement, for example studies of their role as efficient ketosteroid isomerases and as enzymes involved in the biosynthesis of moulting hormones in mosquitoes transmitting malaria and yellow fever. In addition to the work directed specifically at enzymes involved in glutathione metabolism and detoxication, Mannervik coauthored texts on molecular toxicology. He also studied various more general aspects of enzymology, including graphical analysis, error structure of kinetic experiments, weighting of observations, regression methods, directed enzyme evolution, and discrimination between models. Major contributions were more recently directed to the evolution of novel functions by in vitro protein evolution.
=== States of matter === Metastable states of matter (also referred as metastates) range from melting solids (or freezing liquids), boiling liquids (or condensing gases) and sublimating solids to supercooled liquids or superheated liquid-gas mixtures. Extremely pure, supercooled water stays liquid below 0 °C and remains so until applied vibrations or condensing seed doping initiates crystallization centers. This is a common situation for the droplets of atmospheric clouds.
== Career == After a postdoctoral fellowship at the University of Southern Denmark in Odense, Mann became group leader at the European Molecular Biology Laboratory (EMBL) in Heidelberg. Later he went back to Odense as a professor of bioinformatics. Since 2005 he has been a director at the Max Planck Institute of Biochemistry in Martinsried near Munich. In addition, he became a principal investigator at the Novo Nordisk Foundation Center for Protein Research in Copenhagen. From his research group in Martinsried originated in 2016 PreOmics, a company commercializing sample prep sets, and EVOSEP, a company commercializing protein analysis equipment. His work has impact in various fields of mass spectrometry-based proteomics:
Sources: en.wikipedia.org
5 October The New York Times summarizes those awarded Nobel Prizes in the Sciences for the year 2022: Physiology or Medicine (October 3): Svante Pääbo for discoveries involving genomes of extinct hominins Physics (October 4): Alain Aspect, John F. Clauser and Anton Zeilinger for work in quantum technology Chemistry (October 5): Carolyn R. Bertozzi, Morten Meldal and K. Barry Sharpless for studies on click chemistry and bioorthogonal chemistry. Scientists report the discovery of ongoing transfer of mitochondrial DNA into DNA in the cell nucleus. Previously, nuclear-mitochondrial segments (NUMT) were thought to have arisen only long ago. 66 thousand whole-genome sequences indicate this currently occurs as frequent as once in every ~4,000 human births. Researchers outline the large potentials and benefits of marine algae-based aquaculture for the development of a future healthy and sustainable food system. Scientists demonstrate the use of organoids for the study of brain development, identifying and investigating genetic switches that have a significant impact on it using single-cell transcriptome readouts.
Hyperpolarization A change in a cell’s membrane potential that makes it more negative, decreasing the likelihood of firing an action potential. Hypoglossal nerve (Cranial Nerve XII) A cranial nerve responsible for controlling the muscles of the tongue. Damage can cause slurred speech and difficulty swallowing. Hypothalamus A region of the brain below the thalamus that regulates homeostatic functions such as hunger, thirst, body temperature, and circadian rhythms. It controls the pituitary gland and links the nervous and endocrine systems.
== History == In 1819, after the Treaty of Singapore was signed on 6 February and modern Singapore was born, Sir Stamford Raffles declared a policy that all forms are gambling are prohibited. However, the first Resident of Singapore, William Farquhar, established a gambling farm which frustrated Raffles, one of the many reasons leading to Raffles' removal of Farquhar as resident of Singapore. In 1823, after removing Farquhar, Raffles published a Regulation which banned gaming houses and cockfighting pits. Gamblers and owners of gaming houses and cockfighting pits would be punished with 80 blows with a cudgel, gaming stakes confiscated, gaming house confiscated and to wear a heavy wooden collar for a month. However, Farquhar's replacement, John Crawfurd, wrote to the Supreme Government advocating licensing gambling in Singapore and that the Chinese community had appealed to him to suspend Raffle's regulation. Licensed gambling continued to flourish under Crawfurd's governance with gambling profits doubled from 15,000 to 30,000 pounds from 1823 to 1826. In 1827, the Grand Jury made a presentation against gaming farms, Crawfurd referred them as "idiots". Gambling farms were frequently debated in the following years such that in the 1860s, the Secretary of State for the Colonies, Henry Pelham-Clinton, 5th Duke of Newcastle, launched an inquiry over the gambling farms. In 1842, the Singapore Sporting Club was founded by Scottish merchant William Henry Macleod Read to operate the Serangoon Road Race Course at Farrer Park Field.
== Human research == As of 2025, only limited human clinical data on D-ribose-L-cysteine have been published. A small randomized, placebo-controlled pilot trial conducted in 2023 evaluated the effect of a D-ribose-L-cysteine-containing supplement on serum glutathione levels in healthy adults over a 28-day period. According to results released by the study sponsor, participants receiving D-ribose-L-cysteine experienced a statistically significant increase in serum glutathione relative to baseline, with larger increases observed in older participants. The trial has not yet been independently replicated, and full peer-reviewed publication of the data has not been confirmed. Accordingly, the clinical significance of these findings remains preliminary.
The roles of these residues are analogous or the same as the previously described Sortases, in that His and Asp play a supporting role in interacting with the target residue, while the Cys forms a thioester with a carboxyl group for a later nucleophilic attack by a primary amine, in this case due to interest that of Lysine. Though the similarities to sortase catalytically start to end there, as the enzyme and the family is dependent on calcium, which plays a crucial structural role in holding a tight conformation of the enzyme. The TGases, also have a very different substrate specificity in that they target specifically the middle Gln, in the sequence 'Gln-Gln-Val'. The general substrate specificity, i.e. the specific protein is due to the general structure of different TGases which targets them to the substrate. The specificity has been noted in TGases such that different TGases will react with different Gln's on the same protein, signifying that the enzymes have a very specific initial targeting. It has also been shown to have some specificity as to which target Lysine it transfers the protein to, as in the case of Factor XIII, where the adjacent residue to the Lys decides whether the reaction will occur. Thus while the TGases may initially seem like a eukaryotic sortase, they stand on their own as separate set of enzymes. Another case of an isopeptide linking enzyme for structural purposes is the actin cross-linking domain (ACD) of the MARTX toxin protein generated by V. cholerae.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.